VALPARIN XR IN THE TREATMENT OF EPILEPSY (А REVIEW OF LITERATURE AND A DESCRIPTION OF CLINICAL CASES)
https://doi.org/10.17650/2073-8803-2015-10-3-37-42
Abstract
Although epileptologists have a lot of antiepileptic drugs (AEDs) at their disposal now and there are more than 10 novel AEDs; until the present time, two groups of drugs (valproic acid and carbamazepine, which were designed in the 1970s) have remained the gold standard for the treatment of epilepsy. These 2 AEDs are called traditional or standard and the European literature on epileptology describes them as first-choice anticonvulsants. Carbamazepine has a narrower spectrum of therapeutic action and may aggravate a few types of seizures. On the contrary, valproates are effective in all forms of epilepsy, both focal and generalized ones. The anticonvulsant properties of valproic acid were discovered in 1962. Now valproates are successfully used in various age groups of patients with different forms of epilepsy and types of seizures during both mono- and polytherapy in more than 100 countries of Europe and the world, by firmly holding the leading position. A lot of cheaper valproic acid generic drugs have emerged in clinical practice in the past decades. By and large, almost 20 valproates that have one common active ingredient (valproic acid) and are commonly used to treat epilepsy are now available on the global pharmaceutical market.
The authors give the results of trials and describe their own experience with Valparin XR, an extended-release valproic acid drug. The results of the trials and clinical experience show the efficacy and good tolerability of Valparin XR in the treatment of epilepsy.
About the Authors
N. V. Freidkova
Svt. Luka’s Institute of Child Neurology and Epilepsy
Russian Federation
6 Svetlaya St., Puchkovo, Troitsk, Moscow, 143396
Russian Federation
6 Svetlaya St., Puchkovo, Troitsk, Moscow, 143396
O. A. Pylaeva
Svt. Luka’s Institute of Child Neurology and Epilepsy
Russian Federation
6 Svetlaya St., Puchkovo, Troitsk, Moscow, 143396
Russian Federation
6 Svetlaya St., Puchkovo, Troitsk, Moscow, 143396
K. Yu. Mukhin
Svt. Luka’s Institute of Child Neurology and Epilepsy
Russian Federation
6 Svetlaya St., Puchkovo, Troitsk, Moscow, 143396
Russian Federation
6 Svetlaya St., Puchkovo, Troitsk, Moscow, 143396
References
1. Артемова И.Ю., Бадалян О.Л., Богомазова М.А. и др. Опыт применения генерического вальпроата у взрослых пациентов с фокальными формами эпилепсии. Эпилепсия и пароксизмальные состояния 2013;5(1):6–10. [Artyomova I.Yu., Badalyan O.L., Bogomazova M.A. et al. Experience of application of generic valproate in adult patients with focal forms of epilepsy. Epilepsiya i paroksizmal'nye sostoyaniya = Epilepsy and Paroxysmal States 2013;5(1):6–10. (In Russ.)].
2. Громов С.А., Липатова Л.В. Опыт применения дженерика Вальпарин ХР при лечении эпилепсии. Журнал неврологии и психиатрии им. С.С. Корсакова 2007;107(10): 44–6. [Gromov S.A., Lipatova L.V. Experience of application of generic Valparin XP for treatment of epilepsy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatrics 2007;107(10):44–6. (In Russ.)].
3. Гузева В.И. Эпилепсия и неэпилептические пароксизмальные состояния у детей. М.: МИА, 2007. С. 31–55. [Guzeva V.I. Epilepsy and non-epileptic paroxysmal states of children. Moscow: MIA, 2007. Pp. 31–55. (In Russ.)].
4. Карлов В.А. Эпилепсия у детей и взрослых женщин и мужчин. М.: Медицина, 2010. 720 с. [Karlov V.A. Epilepsy of children and adult males and females. Moscow: Meditsina, 2010. 720 p. (In Russ.)].
5. Мухин К.Ю., Миронов М.Б., Петрухин А.С. Эпилептические синдромы. Диагностика и терапия. 3-е изд. М.: ООО «Системные решения», 2014. С. 353–64. [Mukhin K.Yu., Mironov M.B., Petrukhin A.S. Epileptic syndromes. diagnostics and therapy. 3rd ed. Moscow: Systemnye Resheniya LLC, 2014. Pp. 353–64. (In Russ.)].
6. Мухин К.Ю., Петрухин А.С. Идиопатические формы эпилепсии: систематика, диагностика, терапия. М.: Арт-Бизнес-Центр, 2000. 320 с. [Mukhin K.Yu., Petrukhin A.S. Idiopathic forms of epilepsy: systematics, diagnostics, therapy. Moscow: Art-Business-Center, 2000. 320 p. (In Russ.)].
7. Мухин К.Ю., Петрухин А.С., Рыкова Е.А. Побочные эффекты антиконвульсантов при лечении идиопатической генерализованной эпилепсии. Журнал неврологии и психиатрии им. С.С. Корсакова 1997;7:25–31. [Mukhin K.Yu., Petrukhin A.S., Rykova E.A. Side effects of anticonvulsants in treatment of idiopathic generalized epilepsy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatrics 1997;7:25–31. (In Russ.)].
8. Петрухин А.С., Мухин К.Ю., Благосклонова Н.К., Алиханов А.А. Эпилептология детского возраста. М.: Медицина, 2000. С. 547–618. [Petrukhin A.S., Mukhin K.Yu., Blagosklonova N.K., Alikhanov A.A. Pediatric epileptology. Moscow: Meditsina, 2000. Pp. 547–618. (In Russ.)].
9. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic Disord 2002;4(3):217–25.
10. Bertsche A., Neininger M.P., Dahse A.J. et al. Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness. Eur J Pediatr 2014;173(1): 87–92.
11. Burton B.S. On the propyl derivatives and decomposition products of ethylacetoacetate. Am Chem J 1882;3:385–95.
12. Callaghan N., Kenny R.A., O'Neill B. et al. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985;48(7):639–44.
13. Chadwick D., Marson T. Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients. Epilepsia 2007;48(7):1259–63.
14. de Silva M., MacArdle B., McGowan M. et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347(9003):709–13.
15. Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 2006;8(2):113–29.
16. Meunier H., Carraz G., Meunier Y. et al. Рharmacodynamiс рroprietes of Ndipropylacetic acid. Therapie 1963;18: 435–8.
17. Mula M., Sander J.W. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007;30(7):555–67.
18. Nicolson A., Appleton R.E., Chadwick D.W., Smith D.F. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004;75(1):75–9.
19. Panayiotopoulos C.P. A Clinical Guide to еpileptic syndromes and their treatment. Springer, 2007. Pр. 155–84.
20. Panayiotopoulos С.P. A Clinical Guide to epileptic syndromes and their treatment. Springer, 2010. 654 р.
21. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16(10):695–714.
22. Stephen L.J. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging 2003;20(2):141–52.
Review
For citations:
Freidkova N.V., Pylaeva O.A., Mukhin K.Yu. VALPARIN XR IN THE TREATMENT OF EPILEPSY (А REVIEW OF LITERATURE AND A DESCRIPTION OF CLINICAL CASES). Russian Journal of Child Neurology. 2015;10(3):37-42. (In Russ.) https://doi.org/10.17650/2073-8803-2015-10-3-37-42
Views:
1670
Email this article 